HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esmon, C. T. Search for Related Content PubMed PubMed Citation Articles by Esmon, C. T.

The Protein C Pathway^*

^* Investigator, Howard Hughes Medical Institute, Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.

Correspondence to: Charles T. Esmon, PhD, Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th St, Oklahoma City, OK 73104; e-mail: Charles-Esmon{at}omrf.ouhsc.edu

The protein C anticoagulant pathway serves as a major system for controlling thrombosis, limiting inflammatory responses, and potentially decreasing endothelial cell apoptosis in response to inflammatory cytokines and ischemia. The essential components of the pathway involve thrombin, thrombomodulin, the endothelial cell protein C receptor (EPCR), protein C, and protein S. Thrombomodulin binds thrombin, directly inhibiting its clotting and cell activation potential while at the same time augmenting protein C (and thrombin activatable fibrinolysis inhibitor [TAFI]) activation. Furthermore, thrombin bound to thrombomodulin is inactivated by plasma protease inhibitors > 20 times faster than free thrombin, resulting in increased clearance of thrombin from the circulation. The inhibited thrombin rapidly dissociates from thrombomodulin, regenerating the anticoagulant surface. Thrombomodulin also has direct anti-inflammatory activity, minimizing cytokine formation in the endothelium and decreasing leukocyte-endothelial cell adhesion. EPCR augments protein C activation approximately 20-fold in vivo by binding protein C and presenting it to the thrombin-thrombomodulin activation complex. Activated protein C (APC) retains its ability to bind EPCR, and this complex appears to be involved in some of the cellular signaling mechanisms that down-regulate inflammatory cytokine formation (tumor necrosis factor, interleukin-6). Once APC dissociates from EPCR, it binds to protein S on appropriate cell surfaces where it inactivates factors Va and VIIIa, thereby inhibiting further thrombin generation. Clinical studies reveal that deficiencies of protein C lead to microvascular thrombosis (purpura fulminans). During severe sepsis, a combination of protein C consumption, protein S inactivation, and reduction in activity of the activation complex by oxidation, cytokine-mediated down-regulation, and proteolytic release of the activation components sets in motion conditions that would favor an acquired defect in the protein C pathway, which in turn favors microvascular thrombosis, increased leukocyte adhesion, and increased cytokine formation. APC has been shown clinically to protect patients with severe sepsis. Protein C and thrombomodulin are in early stage clinical trials for this disease, and each has distinct potential advantages and disadvantages relative to APC.

Key Words: endothelial cell protein C receptor • endothelium • leukocytes • protein C • sepsis • thrombin • thrombosis

This article has been cited by other articles:

				T. Orfeo, S. Butenas, K. E. Brummel-Ziedins, and K. G. Mann The Tissue Factor Requirement in Blood Coagulation J. Biol. Chem., December 30, 2005; 280(52): 42887 - 42896. [Abstract] [Full Text] [PDF]

				M. David-Dufilho, E. M.-V. Brussel, G. Topal, L. Walch, A. Brunet, and F. Rendu Endothelial Thrombomodulin Induces Ca2+ Signals and Nitric Oxide Synthesis through Epidermal Growth Factor Receptor Kinase and Calmodulin Kinase II J. Biol. Chem., October 28, 2005; 280(43): 35999 - 36006. [Abstract] [Full Text] [PDF]

				S. Weijer, C. W. Wieland, S. Florquin, and T. van der Poll A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis Blood, October 15, 2005; 106(8): 2761 - 2768. [Abstract] [Full Text] [PDF]

				C. C Tzioupis, S. Katsoulis, N. Manidakis, and P. V Giannoudis The immuno-inflammatory response to trauma Trauma, October 1, 2005; 7(4): 171 - 183. [Abstract] [PDF]

				C. V. Denis, S. J. Roberts, T. M. Hackeng, and P. J. Lenting In Vivo Clearance of Human Protein S in a Mouse Model: Influence of C4b-Binding Protein and the Heerlen Polymorphism Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2209 - 2215. [Abstract] [Full Text] [PDF]

				M. E. Papaconstantinou, C. J. Carrell, A. O. Pineda, K. M. Bobofchak, F. S. Mathews, C. S. Flordellis, M. E. Maragoudakis, N. E. Tsopanoglou, and E. Di Cera Thrombin Functions through Its RGD Sequence in a Non-canonical Conformation J. Biol. Chem., August 19, 2005; 280(33): 29393 - 29396. [Abstract] [Full Text] [PDF]

				B. Dahlback and B. O. Villoutreix Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure-Function Relationships and Molecular Recognition Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1311 - 1320. [Abstract] [Full Text] [PDF]

				T. van der Poll, M. Levi, J. A. Nick, and E. Abraham Activated Protein C Inhibits Local Coagulation after Intrapulmonary Delivery of Endotoxin in Humans Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1125 - 1128. [Abstract] [Full Text] [PDF]

				C. Feistritzer and M. Riewald Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation Blood, April 15, 2005; 105(8): 3178 - 3184. [Abstract] [Full Text] [PDF]

				M. J. Ludeman, H. Kataoka, Y. Srinivasan, N. L. Esmon, C. T. Esmon, and S. R. Coughlin PAR1 Cleavage and Signaling in Response to Activated Protein C and Thrombin J. Biol. Chem., April 1, 2005; 280(13): 13122 - 13128. [Abstract] [Full Text] [PDF]

				H. Xu, L. A. Bush, A. O. Pineda, S. Caccia, and E. Di Cera Thrombomodulin Changes the Molecular Surface of Interaction and the Rate of Complex Formation between Thrombin and Protein C J. Biol. Chem., March 4, 2005; 280(9): 7956 - 7961. [Abstract] [Full Text] [PDF]

				A. Undas, K. E. Brummel-Ziedins, and K. G. Mann Statins and Blood Coagulation Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 287 - 294. [Abstract] [Full Text] [PDF]

				J. Hirsh, M. O'Donnell, and J. I. Weitz New anticoagulants Blood, January 15, 2005; 105(2): 453 - 463. [Abstract] [Full Text] [PDF]

				B. S. Donahue The Response to Activated Protein C After Cardiopulmonary Bypass: Impact of Factor V Leiden Anesth. Analg., December 1, 2004; 99(6): 1598 - 1603. [Abstract] [Full Text] [PDF]

				Y. M. Fortenberry, H. C. Whinna, H. R. Gentry, T. Myles, L. L. K. Leung, and F. C. Church Molecular Mapping of the Thrombin-Heparin Cofactor II Complex J. Biol. Chem., October 8, 2004; 279(41): 43237 - 43244. [Abstract] [Full Text] [PDF]

				K. Shim, H. Zhu, L. A. Westfield, and J. E. Sadler A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury Blood, July 15, 2004; 104(2): 415 - 419. [Abstract] [Full Text] [PDF]